People in the News

Nov 05, 2018

Oved Amitay

Centogene has appointed Oved Amitay its chief business officer. He has almost 30 years of commercial and development experience with a focus on orphan drugs for patients with rare genetic diseases. Amitay joins Centogene from Arrett Neuroscience where he was president and COO. Prior to that he was VP, head of commercial at Alnylam Pharmaceuticals. 

Nov 02, 2018

Peter Collins

Peter Collins has stepped down as chief business officer and director of Premaitha Health, effective November 1. Previously, he was vice president and head of diagnostics at GlaxoSmithKline.

Nov 01, 2018

Susan Rolih

Meridian Bioscience said this week that Susan Rolih, executive VP of global regulatory and quality systems, will retire on Nov. 30, 2018. She worked for the firm for 18 years and is expected to serve as a consultant on an as-requested basis with matters related to FDA remediation efforts at the firm's Magellan Diagnostics business, among other matters.

Nov 01, 2018

Jan Groen

Liquid biopsy firm Angle has appointed Jan Groen as a non-executive director, effective Nov. 1. He is currently president and CEO of MDxHealth. Prior to joining that firm, he was president of US operations and global chief operating officer at Agendia. Groen is also a non-executive board member of SPL Medical. 

Nov 01, 2018

Jason Gammack

Gene editing technology company Inscripta has appointed Jason Gammack as its first chief commercial officer. Gammack will design and oversee Inscripta's sales, marketing, business development, and customer support operations. He most recently served as vice president of Qiagen's life science business, where he led the development of the life science portfolio and go-to-market strategy. Prior to Qiagen, Gammack developed commercialization growth strategies at bioinformatics company Ingenuity Systems, which was acquired by Qiagen in 2013, and has also held senior leadership roles at Sigma-Aldrich, Life Technologies, Affymetrix, and Promega.  

Nov 01, 2018

Adam Margolin, Eric Schadt

Mount Sinai’s School of Medicine has hired Adam Margolin, former director of computational biology at Oregon Health & Science University, to lead a new initiative on data science and precision medicine. Margolin will take on the positions previously held by Eric Schadt, who was hired in 2011 to lead Mount Sinai’s programs in data science and genomics. Schadt will continue at Mount Sinai in his role as dean for precision medicine at the school of medicine. He will also remain CEO of Mount Sinai diagnostics spinout Sema4, which provides noninvasive prenatal screening, genetic carrier screening, newborn genetic disease testing, and tumor genetic testing to personalize cancer treatments.

Oct 31, 2018

Maureen Cronin

HTG Molecular Diagnostics has appointed Maureen Cronin as its CSO and senior vice president, effective Nov. 16. Cronin served as executive director of strategic information management for Celgene from 2012 to 2017. Before that, she was senior vice president of research and product development for Foundation Medicine. She also served as VP of translational research and senior director of technology development at Genomic Health.

Oct 31, 2018

Laura Clague

Laura Clague has been appointed to the board of directors of Fluidigm. She is the CFO of Retrophin. Previously, she was the CFO of the San Diego and Ohio operations of Amylin Pharmaceuticals, following the company's acquisition by Bristol-Myers Squibb. Prior to that, she was vice president, corporate controller, and principal accounting officer at Amylin, as well as CFO of Amylin's collaboration with Eli Lilly and Company. Clague holds a BS in business administration from Menlo College.

Oct 26, 2018

Betsy Hanna

Clinical Genomics has appointed Betsy Hanna as its chief commercial officer. Hanna previous served as president and chief operating officer at Origin. Prior to Origin, she held multiple positions over an eight-year period at J&J, with her most recent position as VP of global strategic marketing for Vision Care.

Oct 25, 2018

Lee Hartwell, Elliott Burkland

Lee Hartwell and Elliott Burkland have joined the board of directors of SEngine Precision Medicine. Hartwell is the former president and director of the Fred Hutch Cancer Research Center. He received the Nobel Prize in physiology or medicine in 2001. Burkland is an investor in SEngine.

Oct 22, 2018

Crane Harris

The San Diego Blood Bank has appointed Crane Harris as the group's Chief Business Officer. He is tasked with generating new partnerships and revenue streams to support the blood bank's mission of saving lives with high-quality blood services in partnership with the community, the group said. Harris previously served as director of business development at Illumina. Prior to Illumina, Harris held positions at La Jolla Pharmaceutical Company in both business development and overseeing the bioinformatics team. Harris has also held positions at Monsanto, the US Environmental Protection Agency, and Saatchi & Saatchi Advertising. 

Oct 18, 2018

Mary Padbury, Katherine Bach Kalin

Clinical Genomics announced the appointments of Mary Padbury and Katherine Bach Kalin to its board. Padbury who will be the chairman of the board, has done intellectual property work for Australian and multinational companies. She was most recently a partner and vice chairman of law firm Ashurst. She currently is chairman of the board for Trans-Tasman IP Attorneys.

Kalin has more than 25 years of experience as a senior executive in the healthcare and professional services industries. Most recently, she led corporate strategy at Celgene. Prior to that, she held leadership roles in marketing, sales, strategy, and new bbusiness development at Johnson & Johnson.

Oct 17, 2018

Daniel Kolk

Daniel Kolk has joined XCR Diagnostics as vice president of clinical development. He previously served as senior director of product development for Hologic, where he led development and US Food and Drug Administration clearance of respiratory assays on Hologic's Panther Fusion system. Prior to this he helped develop human papillomavirus and blood screening products at Gen-Probe, which was acquired by Hologic.

Oct 16, 2018

Tom Copa

Asuragen has hired Tom Copa as its SVP, commercial operations. Copa will lead the global sales, marketing, and customer solutions teams for the firm's diagnostics products business. Prior to Asuragen, Copa served as VP of licensed technologies at Luminex, as well as spending over 16 years as a senior executive in several roles at the firm. 

Oct 12, 2018

Jane Schwebke

Talis Biomedical has appointed Jane Schwebke to its scientific advisory board. Both a professor of medicine in the infectious disease division at the University of Alabama at Birmingham and a consultant to the Jefferson County Department of Health STD clinic, Schwebke previously served as medical director of the Harborview STD Clinic in Seattle and as director for Chicago's STD/HIV Program.

Oct 11, 2018

Jörg Debatin

Jörg Debatin has been appointed chairman of the supervisory board of Hummingbird Diagnostics. Debatin previously served as VP and chief technology officer of GE Healthcare and CEO of Amedes. In addition, he has also served as the medical director and CEO of the University Hospital Hamburg-Eppendorf.

Oct 10, 2018

Richard Yost

Owlstone Medical appointed Richard Yost to its scientific advisory board. He is a professor and head of analytical chemistry at the University of Florida and has particular expertise in tandem mass spectrometry. Yost is the co-inventor of the triple quadrupole mass spectrometer, Owlstone added. 

Oct 09, 2018

Michel Finance

Michel Finance is leaving his post as CEO of Theradiag, the company announced. No reason was given for his departure. Finance will stay on at Theradiag until Dec. 31. A search for his successor has begun. 

Oct 03, 2018

Tom Polen

Tom Polen, who currently serves as president of BD, has been promoted. He will now also serve as BD's Chief Operating Officer. Polen will be responsible for overseeing the firm's three operating segments, its new product development pipeline, and global operations including all manufacturing facilities and supply chain operations. The company has not had a COO since 2016, according to a statement.

Oct 03, 2018

Hayden Jeffreys

Hayden Jeffreys has become group commercial director at Premaitha Health. He joined the company from Cambridge Epigenetix, where he was chief operating officer. Before that, he was interim CEO at ERBA Diagnostics. Jeffreys holds an MSc in management studies from the University of Oxford and a BSc in genetics from Cardiff University.

Oct 02, 2018

Lawrence Culp

Former Danaher President and CEO Lawrence Culp was named the Chairman and CEO of GE on Oct. 1, effective immediately. He replaces John Flannery in the two positions. Culp has been a member of GE's board since April and led Danaher between 2000 and 2014. 

Sep 27, 2018

Jonathan Seaton

GenomOncology has appointed Jonathan Seaton to its board of directors. Seaton is senior vice president for corporate development at Illumina. Previously, he was vice president of strategy and business development for life sciences at Becton Dickinson and has held multiple roles at Roche.

Sep 25, 2018

Christiane Honisch

Pathoquest announced today that it has appointed Christiane Honisch as an independent member of the firm's board of directors. With over 15 years of experience developing markers, assays, software, and technology for infectious disease detection, Honisch is currently head of global business intelligence and development at Eppendorf. Prior to Eppendorf, Honisch served as director of microbiology markets at Illumina. Before working at Illumina, Honisch served as director of infectious disease research at Roche Molecular Diagnostics.

Sep 24, 2018

John Kraeutler, David Phillips, Felicia Williams

John (Jack) Kraeutler has retired from his position as Meridian Bioscience's executive chairman of the board, effective Sept. 30, 2018. Kraeutler retired as CEO of the firm last year after 25 years in that position. Meridian has appointed David Phillips as the new chairman of the board, and has also elected Felicia Williams to the board of directors and to serve on the firm's audit committee, effective September 20, 2018. Williams previously served in financial positions at Macy's and Coca-Cola.

Sep 24, 2018

Leslie Auld, Warren Whitehead

GeneNews announced today that Leslie Auld has resigned as the firm's CFO and director. 

In addition, the firm has has appointed Warren Whitehead as its chief accountant. Whitehead is currently the chairman of Plantform and chair of the audit committee at Aptose Biosciences.

Prior to GeneNews, White served as CFO of ProMis Neurosciences; CFO of Arius Research before it was purchased in Roche in 2008; and former CFO of Labopharm, where he completed a series of public equity financings. 

Pages

Customers might want to consider what they might learn about their risk of diseases like Alzheimer's before snagging the genetic testing kits that are on many gift guides this year, NJ.com writes.

The Wall Street Journal reports there is uncertainty surrounding whether He Jiankui's embryo editing did what he said it did.

Stat News reports that the pause on procuring fetal tissue for intramural US National Institutes of Health research will soon affect additional labs there.

In Nature this week: genomic analysis of the invasive fall webworm, amp of constrained coding regions within the human genome, and more.